Search Results for: ATP1B1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel CD84 CD84 molecule
  • Cell surface interactions at the vascular wall
Novel CREG1 cellular repressor of E1A stimulated genes 1
  • Neutrophil degranulation
Novel HCRTR1 hypocretin receptor 1
  • Orexin and neuropeptides FF and QRFP bind to their respective receptors
  • G alpha (q) signalling events
  • Suvorexant
  • Lemborexant
Novel PRRX1 paired related homeobox 1
Novel SERPINC1 serpin family C member 1
  • Intrinsic Pathway of Fibrin Clot Formation
  • Common Pathway of Fibrin Clot Formation
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • Post-translational protein phosphorylation
  • Ardeparin
  • Fondaparinux
  • Heparin
  • Enoxaparin
  • N-Formylmethionine
  • SR-123781A
  • Sulodexide
  • Danaparoid
  • Dalteparin
  • Tinzaparin
  • Nadroparin
  • Copper
  • Protamine sulfate
  • Bemiparin
  • Antithrombin III human
  • Inherited thrombophilia
Novel THOC1 THO complex 1
  • Transport of Mature mRNA derived from an Intron-Containing Transcript
  • mRNA 3'-end processing
  • RNA Polymerase II Transcription Termination
Novel TM4SF1 transmembrane 4 L six family member 1
AGTR1 angiotensin II receptor type 1
  • Peptide ligand-binding receptors
  • G alpha (q) signalling events
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • Valsartan
  • Olmesartan
  • Losartan
  • Candesartan cilexetil
  • Eprosartan
  • Telmisartan
  • Irbesartan
  • Forasartan
  • Saprisartan
  • Tasosartan
  • CYT006-AngQb
  • Azilsartan medoxomil
  • Fimasartan
  • Angiotensin II
  • Candesartan
  • Renal tubular dysgenesis
BACE1 beta-secretase 1
  • Amyloid fiber formation
  • MMI-175
  • CTS-21166
  • N-[amino(imino)methyl]-2-(2,5-diphenyl-1H-pyrrol-1-yl)acetamide
  • N-[(5R,14R)-5-AMINO-5,14-DIMETHYL-4-OXO-3-OXA-18-AZATRICYCLO[15.3.1.1~7,11~]DOCOSA-1(21),7(22),8,10,17,19-HEXAEN-19-YL]-N-METHYLMETHANESULFONAMIDE
  • N-[amino(imino)methyl]-2-[2-(2-chlorophenyl)-4-(4-propoxyphenyl)-3-thienyl]acetamide
  • 4-(4-FLUOROBENZYL)PIPERIDINE
  • N-{2-methyl-5-[(6-phenylpyrimidin-4-yl)amino]phenyl}methanesulfonamide
  • 6-[2-(1H-INDOL-6-YL)ETHYL]PYRIDIN-2-AMINE
  • 6-[2-(3'-METHOXYBIPHENYL-3-YL)ETHYL]PYRIDIN-2-AMINE
  • N~3~-BENZYLPYRIDINE-2,3-DIAMINE
  • N~3~-(3-PYRIDIN-3-YLBENZYL)PYRIDINE-2,3-DIAMINE
  • N~3~-[3-(5-METHOXYPYRIDIN-3-YL)BENZYL]PYRIDINE-2,3-DIAMINE
  • 4-(2-aminoethyl)-2-cyclohexylphenol
  • 4-(2-aminoethyl)-2-ethylphenol
  • 4-[(1S)-1-(3-fluoro-4-methoxyphenyl)-2-(2-methoxy-5-nitrophenyl)ethyl]-1H-imidazol-2-amine
  • (6R)-2-amino-6-[2-(3'-methoxybiphenyl-3-yl)ethyl]-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one
  • 2-amino-6-[2-(1H-indol-6-yl)ethyl]pyrimidin-4(3H)-one
  • (2S)-1-(2,5-dimethylphenoxy)-3-morpholin-4-ylpropan-2-ol
  • N-(1-benzylpiperidin-4-yl)-4-sulfanylbutanamide
  • N-[1-(2,6-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide
  • (2S)-4-(4-fluorobenzyl)-N-(2-sulfanylethyl)piperazine-2-carboxamide
  • (2S)-4-(4-fluorobenzyl)-N-(3-sulfanylpropyl)piperazine-2-carboxamide
  • N-[1-(5-bromo-2,3-dimethoxybenzyl)piperidin-4-yl]-4-sulfanylbutanamide
  • (6S)-2-amino-6-(3'-methoxybiphenyl-3-yl)-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one
  • N~3~-[3-(1H-INDOL-6-YL)BENZYL]PYRIDINE-2,3-DIAMINE
  • N~3~-[5-(1H-INDOL-6-YL)-2-(PYRIDIN-2-YLMETHOXY)BENZYL]PYRIDINE-2,3-DIAMINE
  • 3-(2-AMINO-6-BENZOYLQUINAZOLIN-3(4H)-YL)-N-CYCLOHEXYL-N-METHYLPROPANAMIDE
  • Verubecestat
BARD1 BRCA1 associated RING domain 1
  • HDR through Single Strand Annealing (SSA)
  • HDR through Homologous Recombination (HRR)
  • UCH proteinases
  • Metalloprotease DUBs
  • Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Resolution of D-loop Structures through Holliday Junction Intermediates
  • Nonhomologous End-Joining (NHEJ)
  • Homologous DNA Pairing and Strand Exchange
  • Processing of DNA double-strand break ends
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • Regulation of TP53 Activity through Phosphorylation
  • G2/M DNA damage checkpoint
  • Defective DNA double strand break response due to BRCA1 loss of function
  • Defective DNA double strand break response due to BARD1 loss of function
BRCA1 BRCA1 DNA repair associated
  • Meiotic synapsis
  • SUMOylation of DNA damage response and repair proteins
  • HDR through Single Strand Annealing (SSA)
  • HDR through Homologous Recombination (HRR)
  • Metalloprotease DUBs
  • Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Resolution of D-loop Structures through Holliday Junction Intermediates
  • Nonhomologous End-Joining (NHEJ)
  • Homologous DNA Pairing and Strand Exchange
  • Processing of DNA double-strand break ends
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • TP53 Regulates Transcription of DNA Repair Genes
  • Regulation of TP53 Activity through Phosphorylation
  • G2/M DNA damage checkpoint
  • Transcriptional Regulation by E2F6
  • Meiotic recombination
  • Defective DNA double strand break response due to BRCA1 loss of function
  • Defective DNA double strand break response due to BARD1 loss of function
  • Breast cancer
  • Ovarian cancer
CRIP2 cysteine rich protein 2
DDAH2 dimethylarginine dimethylaminohydrolase 2
  • eNOS activation
  • Citrulline
EGFR epidermal growth factor receptor
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Cetuximab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • AV-412
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • PD-168393
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Foreskin keratinocyte (neonatal)
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Dacomitinib
  • Fostamatinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Zanubrutinib
  • Abivertinib
  • Choriocarcinoma
  • Gastric cancer
  • Bladder cancer
  • Oral cancer
  • Glioma
  • Laryngeal cancer
  • Cervical cancer
  • Esophageal cancer
EZH2 enhancer of zeste 2 polycomb repressive complex 2 subunit
  • PRC2 methylates histones and DNA
  • Oxidative Stress Induced Senescence
  • PKMTs methylate histone lysines
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • Regulation of PTEN gene transcription
  • Regulation of PTEN gene transcription
  • Transcriptional Regulation by E2F6
  • HCMV Early Events
  • Tazemetostat
  • CPI-1205
FXYD1 FXYD domain containing ion transport regulator 1
  • Ion homeostasis
  • Ion transport by P-type ATPases
  • Potential therapeutics for SARS
FXYD7 FXYD domain containing ion transport regulator 7
  • Ion homeostasis
  • Ion transport by P-type ATPases
  • Potential therapeutics for SARS
GCH1 GTP cyclohydrolase 1
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • Guanine
  • Primary torsion dystonia (PTD)
  • Phenylketonuria (PKU); Hyperphenylalaninemia, BH4-deficient
HTR2B 5-hydroxytryptamine receptor 2B
  • Serotonin receptors
  • G alpha (q) signalling events
  • Methysergide
  • Cabergoline
  • Zolmitriptan
  • Dihydroergotamine
  • Methylergometrine
  • Chlorpromazine
  • Triflupromazine
  • Amoxapine
  • Fenfluramine
  • Lisuride
  • Ergotamine
  • Apomorphine
  • Paroxetine
  • Paroxetine
  • Minaprine
  • Cyclobenzaprine
  • Ergoloid mesylate
  • Tegaserod
  • Doxepin
  • Pergolide
  • Bromocriptine
  • Ketamine
  • Aripiprazole
  • Chlorprothixene
  • Clomipramine
  • Yohimbine
  • Midomafetamine
  • Lysergic acid diethylamide
  • OPC-28326
  • Epicept NP-1
  • PRX-08066
  • Cariprazine
  • Mianserin
  • Pizotifen
  • Asenapine
  • Ocaperidone
  • Esmirtazapine
  • Pipamperone
  • Setiptiline
  • Dihydroergocornine
  • Gilteritinib
  • Tiapride
  • Dihydroergocristine
KMT2B lysine methyltransferase 2B
  • PKMTs methylate histone lysines
  • RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function

Page 1 out of 2 pages